Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | OGT | O15294 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PTP4A3 | O75365 | 3/20 | 0.41 |
| ▸ | PTP4A2 | Q12974 | 2/20 | 0.41 |
| ▸ | PTP4A1 | Q93096 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498482 | 0.71 | NOS1 (0.41) | ERCC5FEN1F2CFDPDGFRA | |
| SCHEMBL1884360 | 0.70 | FEN1 (1.00) | ERCC5FEN1KCNH2RAB9ASMN1; SMN2 | |
| SCHEMBL3548193 | 0.69 | ERCC5 (0.53) | ERCC5FEN1F2CFDPDGFRA | |
| SCHEMBL6004269 | 0.68 | ERCC5 (0.49) | ERCC5FEN1KCNH2CDC7DBF4 | |
| SCHEMBL21442180 | 0.68 | ERCC5 (0.49) | ERCC5FEN1KCNH2CDC7DBF4 | |
| SCHEMBL21658177 | 0.68 | F2 (0.61) | F2CFDPDGFRAMAPK8CDK5 | |
| SCHEMBL17318014 | 0.68 | ERCC5 (0.49) | ERCC5FEN1KCNH2CDC7DBF4 | |
| SCHEMBL9098195 | 0.67 | ERCC5 (0.48) | ERCC5FEN1KCNH2CDC7DBF4 | |
| SCHEMBL17260655 | 0.67 | PDE3B (0.71) | OGTCDC7DBF4MAPTALDH1A1 | |
| SCHEMBL14403068 | 0.66 | F2 (0.34) | ERCC5FEN1F2CFDNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| EP-2363396-A1 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2011-09-07 | — | — | EP | disclosed |
| EP-2361913-A1 | Anti-infective agents | Abbott Laboratories (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | disclosed |
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| EP-1401825-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | VIROCHEM PHARMA INC (CA) | 2009-08-05 | — | — | EP | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| US-20050075331-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2005-04-07 | — | — | US | disclosed |
| US-20040167123-A1 | Anti-infective agents | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040162285-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-08-19 | — | — | US | disclosed |
| US-20040116509-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2004-06-17 | — | — | US | disclosed |
| US-20040097492-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-20 | — | — | US | disclosed |
| US-20040087577-A1 | Anti-infective agents | ABBOTT LABORATORIES | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097492-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ERCC5 2973/4885FEN1 1213/4885KCNH2 4457/4885 |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | ERCC5 4492/4885FEN1 2644/4885KCNH2 2669/4885 |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | ERCC5 4492/4885FEN1 2644/4885KCNH2 2669/4885 |
| US-20040162285-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ERCC5 2973/4885FEN1 1213/4885KCNH2 4457/4885 |
| US-20040167123-A1 | Anti-infective agents | SERPINB1, CYP51A1, ZC3HAV1 | ERCC5 3536/4885FEN1 727/4885KCNH2 4531/4885 |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | ERCC5 4492/4885FEN1 2644/4885KCNH2 2669/4885 |
| US-20050075331-A1 | Anti-infective agents | RPL35, POLI, POLRMT | ERCC5 3596/4885FEN1 1845/4885KCNH2 4631/4885 |
| US-20040087577-A1 | Anti-infective agents | POLR1C, RPL5, POLB | ERCC5 2973/4885FEN1 1213/4885KCNH2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.